Market Events and Forecast | Respiratory | US/EU5 | 2021
In 2019, sales of branded biologics for respiratory indications reached nearly $1.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Related Market Assessment Reports
Report
Binge Eating Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Binge Eating Disorder (US)
Binge eating disorder (BED) is a prevalent condition in the United States; it affects millions of individuals across diverse demographics. BED is characterized by recurrent episodes of excessive…
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete as a result of opioid medications. The treatment of OIC relies on various prescription…
Report
Chronic Obstructive Pulmonary Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Obstructive Pulmonary Disease (US)
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) / inhaled corticosteroid (ICS) fixed-dose combinations (FDCs)—i.e., Trelegy and Breztri—have been gaining traction in…
Report
Diabetic Nephropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Nephropathy (US)
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
